BUDGET IMPACT ANALYSIS (BIA) OF CABAZITAXEL INTRODUCTION IN TREATMENT OF METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) IN RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Kogon, L. [2 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
[2] FGBU NCESMP Minist Hlth Russia, Moscow, Russia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.640
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A132 / A132
页数：1
相关论文
共 50 条
  • [31] Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)
    Nicolini, A
    Mancini, PA
    Ferrari, P
    Anselmi, L
    Tartarelli, G
    Bonazzi, V
    Carpi, A
    Giardino, R
    BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (08) : 447 - 450
  • [32] New standards in the chemotherapy of metastatic hormone-refractory prostate cancer
    Sava, T
    Basso, U
    Porcaro, A
    Cetto, GL
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 53 - 62
  • [33] A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer
    Ferrero, JM
    Foa, C
    Thezenas, S
    Ronchin, P
    Peyrade, F
    Valenza, B
    Lesbats, G
    Garnier, G
    Boublil, JL
    Tchiknavorian, X
    Chevallier, D
    Amiel, J
    ONCOLOGY, 2004, 66 (04) : 281 - 287
  • [34] Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer
    Huan, SD
    Stewart, DJ
    Aitken, SE
    Segal, R
    Yau, JC
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 471 - 474
  • [35] THE USE OF FLUTAMIDE IN HORMONE-REFRACTORY METASTATIC PROSTATE-CANCER
    MCLEOD, DG
    BENSON, RC
    EISENBERGER, MA
    CRAWFORD, ED
    BLUMENSTEIN, BA
    SPICER, D
    SPAULDING, JT
    CANCER, 1993, 72 (12) : 3870 - 3873
  • [36] The changing pattern of management for hormone-refractory, metastatic prostate cancer
    James, N. D.
    Bloomfield, D.
    Luscombe, C.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (03) : 221 - 229
  • [37] The changing pattern of management for hormone-refractory, metastatic prostate cancer
    N D James
    D Bloomfield
    C Luscombe
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 221 - 229
  • [38] Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
    Calcagno, Fabien
    Nguyen, Thierry
    Dobi, Erion
    Villanueva, Cristian
    Curtit, Elsa
    Kim, Stefano
    Montcuquet, Philippe
    Kleinclauss, Francois
    Pivot, Xavier
    Thiery-Vuillemin, Antoine
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 1 - 12
  • [39] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    Yang, Yi-Chun Ou
    Carducci, Michael A.
    Tannock, Ian
    de Wit, Ronald
    Eisenberger, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3965 - 3970
  • [40] A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
    R Collins
    R Trowman
    G Norman
    K Light
    A Birtle
    E Fenwick
    S Palmer
    R Riemsma
    British Journal of Cancer, 2006, 95 : 457 - 462
12345